Table 2 Mutational status of tumors included in the study.

From: An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology

Mutational status

Number of cases (%)

KRAS mutation

149 (35.99%)

No mutation retrieved

108 (26.09%)

EGFR mutation

48 (11.59%)

Other mutation

39 (9.42%)

MET mutation

19 (4.60%)

 MET exon 14 skipping mutation

11 (2.7%)

 MET variant of unknown significance alone

8 (1.94%)

BRAF mutation

19 (4.60%)

ALK translocation

18 (4.35%)

ERBB2 mutation

5 (1.21%)

Technical failure

6 (1.45%)

ROS1 translocation

4 (0.97%)

RET translocation

2 (0.48%)

  1. Data are compiled from the results of IHC, FISH, genotyping and LD-RT-PCR. For the sake of clarity, double mutations have been omitted, explicating the reason why the sum is over 413 (1 case with a KRAS mutation and a MET variant of unknown significance; 1 case with a KRAS mutation and a BRAF mutation; 1 case with an ALK translocation and a MET variant of unknown significance).
Back to article page